Genmab A/S (GMAB.CO)
| Previous close | 1,915.50 |
| Open | 1,919.50 |
| Bid | 1,954.00 x N/A |
| Ask | 1,955.50 x N/A |
| Day's range | 1,919.50 - 1,969.00 |
| 52-week range | 1,825.00 - 2,939.00 |
| Volume | |
| Avg. volume | 129,392 |
| Market cap | 126.757B |
| Beta (5Y monthly) | 0.78 |
| PE ratio (TTM) | 29.58 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Investor's Business Daily
Genmab Takes The Next Step In Its 'Evolution' With A $1.8 Billion Takeover
Genmab stock slumped Wednesday after the Danish biotech announced it will buy privately held ProfoundBio for $1.8 billion.
- Reuters
Denmark's Genmab to acquire ProfoundBio for $1.8 billion
The acquisition will give Genmab worldwide rights to three candidates in clinical development, they said. Genmab shares were down 1.7% at 0955 GMT. Jyske bank analyst Henrik Hallengreen Laustsen said that while the acquisition is seen as slightly positive for Genmab shares, the price is difficult to assess, and added it might be "a bit high".
- Insider Monkey
30 Biggest Biotechnology Companies in the World
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world. If you do not want to learn about the global biotech market, head straight to the 5 Biggest Biotechnology Companies in the World. In the ever-evolving landscape of biotechnology, several companies like Novo Nordisk, Regeneron, and United […]
